IDEAYA Biosciences, Inc. Common StockIDYA
Scheduled
IDEAYA Biosciences, Inc. Common Stock Citigroup’s Biopharma Back to School Summit 2026
Review the key takeaways and the transcript of this earnings call.
Period 2026
Key takeaways
- IDEYA Biosciences is a precision medicine oncology company with a late-stage asset in metastatic melanoma, for which the NDA submission is underway with three of four modules submitted and a potential commercial launch in the first half of next year.
- The company is conducting phase three studies in neoadjuvant and adjuvant settings to expand indications.
- IDEYA 4.9, a DLL3 topo EDC, has received FDA feedback supporting a phase three registrational study for monotherapy approval in extensive stage small cell lung cancer, with overall response rate as the primary endpoint for accelerated approval and overall survival for full approval.
- IDEYA has two collaborations with Roche focusing on pancreatic cancer, combining their MTAP deletion and CDK2A assets with Roche's PAN-RAS and KRAS G12D inhibitors, targeting a significant patient population.
- The company is preparing a US commercial launch with a salesforce of approximately 25 individuals and has hired the base commercial leadership team, with supply chain readiness on track.
- Upcoming data presentations include about 100 patients' data in metastatic melanoma HLA A2 positive group and neoadjuvant studies at ESMO, with detailed response rate, PFS, and overall survival data.
- Dose optimization for the DLL3 asset is ongoing between 2.4 mg/kg and 3.5 mg/kg, with randomized cohorts being evaluated and final dose selection expected to be disclosed.
- IDEYA is advancing other pipeline assets including CAT67, a dual CAT6 and CAT7 inhibitor in dose escalation targeting breast, colorectal, and lung cancers, and exploring combinations with SERD and PAN-RAS/KRAS CRC.
- The company is actively integrating AI tools across drug discovery, clinical site selection, regulatory processes, and commercialization efforts, using platforms such as ChatGPT, Claude, and Copilot.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring